Agilent Announces Higher-Sensitivity XF Analysis Solution for Low Abundant Immune Cell Metabolic Analysis
February 17 2021 - 8:00AM
Business Wire
Enhanced data quality, easier workflow, and more versatile
analytics using fewer cell numbers
Agilent Technologies Inc. (NYSE: A) today introduced the Agilent
Seahorse XF HS Miniplate designed specifically for the Agilent
Seahorse XF HS Mini Analyzer for improved immune cell metabolic
analysis.
Immunology and disease researchers are increasingly using rare,
ex vivo, and genetically engineered cells to build better disease
models. Limitations in the quantities of these cells that they can
produce, however, restrict these researchers in the types of
cellular assays they can perform.
The XF HS Mini is the latest addition to Agilent’s range of
Seahorse XF platforms, which analyze mitochondrial respiration,
glycolysis, and ATP production in live cells, in real-time. These
metabolic measurements enable researchers to better understand cell
health, function, and signaling.
The highly sensitive XF HS Mini analyzer offers improved
performance and precision, requiring fewer cells per well, an
improved more consistent suspension cell workflow, and streamlined
analytics. These improvements enable researchers to confidently
generate XF data from quantity limited or low respiring cell types,
such as immune cells, where measurements were previously not
possible.
“Our cells are highly manipulated immune cells which are
short-lived, costly, and labor-intensive to generate. Obtaining
higher-sensitivity with fewer cell numbers is the ‘make or break’
that enables us to use Agilent’s Seahorse XF technology in our
disease model,” stated Katja Weinacht, M.D., Ph.D., assistant
professor of Pediatrics in the Division of Stem Cell
Transplantation and Regenerative Medicine at Stanford
University.
“As our customers strive to unlock biology in more complex and
specialized in vivo settings, the need to interrogate rarer cell
populations has become evident,” stated David Ferrick, Ph.D.,
senior director of Agilent's Cell Analysis Division. “The improved
sensitivity and precision of the XF HS Mini will open up this new
world of metabolic analysis for these customers.”
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets, delivering
insight and innovation toward improving the quality of life.
Agilent instruments, software, services, solutions, and people
provide trusted answers to customers' most challenging questions.
The company generated revenue of $5.34 billion in fiscal 2020 and
employs 16,400 people worldwide. Information about Agilent is
available at www.agilent.com. To receive the latest Agilent news,
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210217005173/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024